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OBJECTIVE — The purpose of this study was to estimate the progression rates to impaired
glucose regulation (impaired fasting glucose or impaired glucose tolerance) and diabetes in the
Danish population–based Inter99 study and in a high-risk subpopulation, separately.
RESEARCH DESIGN AND METHODS — From a population-based primary preven-
tion study, the Inter99 study, 4,615 individuals without diabetes at baseline and with relevant
follow-up data were divided into a low- and a high-risk group based on a risk estimate of
ischemic heart disease or the presence of risk factors (smoking, hypertension, hypercholester-
olemia, obesity, or impaired glucose tolerance). High-risk individuals (57.1%) were examined
with an oral glucose tolerance test at 1 and 3 years, and all of the participants were reexamined
at the 5-year follow-up. Person-years at risk were calculated. Progression rates to impaired
glucoseregulationanddiabeteswereestimateddirectlyfrombaselinetothe5-yearfollow-upfor
alltheparticipantsandfrombaselinethroughthe1-and3-to5-yearfollow-upexaminationsfor
the high-risk individuals, separately.
RESULTS — Inthecombinedlow-andhigh-riskgroup,2.1individualsper100person-years
progressed from normal glucose tolerance (NGT) to impaired glucose regulation or diabetes.
Among high-risk individuals, 5.8 per 100 person-years with NGT progressed to impaired glu-
cose regulation or diabetes, and 4.9 per 100 person-years progressed from impaired glucose
regulation to diabetes.
CONCLUSIONS — Progression rates to impaired glucose regulation using the current
World Health Organization classiﬁcation criteria were calculated for the ﬁrst time in a large
European population-based study. The progression rates to diabetes show the same pattern as
seen in the few similar European studies.
Diabetes Care 32:606–611, 2009
E
stimates of the future burden of dia-
betes in different populations re-
quire accurate progression rates
frompopulation-basedstudies.Newinci-
dence studies are needed because of
the increasing prevalence of diabetes, the
change in risk factors over time, and the
introduction of new diagnostic criteria.
Previous incidence studies on Caucasians
of European origin have used older deﬁ-
nitions of diabetes (1–4), have ascer-
tained new cases by registries (5) or
primary care records (6), or have only
used fasting plasma glucose (FPG) for the
diagnosis of diabetes (7,8).
Few population-based studies, using
the current World Health Organization
(WHO) classiﬁcation criteria (9), have
calculated progression rates from normal
glucose tolerance (NGT) or impaired glu-
cose regulation (impaired fasting glucose
[IFG] and impaired glucose tolerance
[IGT]) to diabetes in Caucasians of Euro-
pean origin (10–14). None of the Euro-
pean studies have calculated progression
rates to impaired glucose regulation
(10,11,13), and none of these studies are
from the Nordic countries. Because of the
heterogeneity of type 2 diabetes and its
recognized polygenic basis and depen-
dence on environmental factors, there is a
need for population-based, ethnically fo-
cused, and country/continent-speciﬁc
studies of type 2 diabetes incidence (7).
Impaired glucose regulation refers to
a metabolic state between normal glucose
homeostasis and diabetes (9). Although
individuals with isolated IFG (i-IFG) are
characterized by hepatic insulin resis-
tance, individuals with isolated IGT
(i-IGT) are predominantly characterized
by muscle insulin resistance (15). i-IFG
and i-IGT are parallel states that may
progress to the combined state IFG-IGT
or to diabetes. Prospective studies have
shownhigherprogressionratesfromIFG-
IGT to diabetes compared with the pro-
gression from i-IFG or i-IGT to diabetes
(5,10,16). Therefore, in this study we
present the progression rates to and from
the isolated states of impaired glucose
regulation (i-IFG or i-IGT) as well as the
combined state (IFG-IGT). Furthermore,
wehypothesizethatindividualswithIFG-
IGT will progress to diabetes at a higher
rate than individuals with i-IFG or i-IGT.
The aim of this study was to estimate
the progression rates to impaired glucose
regulation and diabetes in the Danish
population–based Inter99 study and in a
high-risk subpopulation, separately. In
addition, our aim was to study the asso-
ciations between progression rates from
i-IFG, i-IGT, or IFG-IGT to diabetes.
RESEARCH DESIGN AND
METHODS— The Inter99 study is a
population-based primary prevention
study on cardiovascular disease and type
2 diabetes. The study population com-
prised all 61,301 individuals born in
1939–1940, 1944–1945, 1949–1950,
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and 1969–1970 living in 11 municipali-
ties in the southwestern part of Copenha-
gen County, Denmark, on 2 December
1998.Fromthestudypopulation,anage-
and sex-stratiﬁed random sample com-
prising 13,016 individuals was drawn.
The sample was a priori randomized into
two groups comprising 90% (group A:
high-intensity intervention) and 10%
(group B: low-intensity intervention) (17).
All 13,016 individuals in groups A
and B were invited to a health screening
programandapersonalriskassessmentof
their absolute 10-year risk of developing
ischemic heart disease (IHD) by the
Copenhagen Risk Score (17). High-risk
individuals were deﬁned as individuals
with an absolute risk of IHD in the upper
quintile of their age and sex strata or with
one or more of the following risk factors:
daily smoker, systolic blood pressure
160 mmHg/antihypertensive therapy,
total cholesterol 7.5 mmol/l, BMI 30
kg/m
2, history of diabetes, or diabetes or
IGT diagnosed at baseline. Based on the
personal risk estimate, each individual
was offered lifestyle counseling dealing
with smoking, physical activity, diet, and
alcohol. High-risk individuals in group A
were further offered lifestyle counseling
in groups on smoking cessation or phys-
ical activity/diet with six meetings during
a4-to6-monthperiod,whereashigh-risk
individuals in group B were referred to
their family physician. Baseline data were
collected from March 1999 until January
2001. The Inter99 study and baseline re-
sults are described in detail elsewhere
(17,18).
All high-risk individuals were rein-
vited at 1 and 3 years for a health exami-
nation including a new risk assessment
andlifestylecounseling.Ifstillathighrisk
atthereexamination,individualsingroup
A were again offered lifestyle counseling
in groups, and individuals in group B
were again referred to their family physi-
cian. All participants at baseline were re-
invited at 5 years for a ﬁnal health
examination.
Study procedure
At each examination, the participants
ﬁlledinaquestionnaireonhealthandlife-
styleinadvance.Inthequestionnaire,na-
tionality was divided into Danish and
Other.
Height was measured without shoes
to the nearest 0.5 cm, weight was mea-
sured without shoes and overcoat to the
nearest 0.1 kg, and BMI was calculated as
weightinkilogramsdividedbythesquare
of height in meters. Waist circumference
was measured to the nearest centimeter
midway between the lower rib margin
and the iliac crest (17,18).
After a minimum8ho ffasting over-
night, all participants without known di-
abetes underwent a standard oral glucose
tolerance test (OGTT) (75 g anhydrous
glucose in 250 ml water) at each exami-
nation. Plasma glucose was measured in
the fasting state and after 120 min. Blood
samples for glucose measurements were
taken in heparin-sodium ﬂuoride tubes,
immediately put on ice and centrifuged,
and plasma was separated within 30 min.
Plasma glucose was analyzed using the
hexokinase/glucose-6-phosphate dehy-
drogenase method (Boehringer Mann-
heim) (17,18).
All participants gave written in-
formed consent before taking part in the
study. The study was approved by the lo-
cal ethics committee (KA 98 155) (17).
Methods and deﬁnitions
Of the 13,016 individuals invited at base-
line, 82 were noneligible because they
had died or could not be traced. Of the
remaining 12,934 individuals, 6,906 par-
ticipated in the investigation. Of these,
122individualswereexcludedbecauseof
alcoholism, drug abuse, or linguistic bar-
riers,leaving6,784(52.5%)foranalysisat
baseline (17,18). In general, the partici-
pation rate was higher in younger women
than in younger men, and it increased
with increasing age until 55 years of age,
after which it declined. The participation
rate was identical in group A (high-
intensity intervention) and group B (low-
intensity intervention) (17).
Glucose tolerance status was classi-
ﬁed according to the 1999 WHO criteria
by a single OGTT (9), and IGT was di-
vided into i-IGT and IFG-IGT. At base-
line, 374 (5.5%) were nonclassiﬁable
because of lack of either FPG or 2-h
plasma glucose measurements, and 404
(6.0%) had either self-reported diabetes
or diabetes diagnosed by the OGTT (18),
leaving 6,006 individuals without diabe-
tes. The high-risk group comprised
57.1% (3,429 of 6,006) at baseline.
At the 5-year follow-up, 1,975 indi-
viduals were lost to follow-up or were
nonclassiﬁable, leaving 4,031 individuals
with relevant data for the progression
rates directly from baseline to 5 years. At
the 1-, 3-, and 5-year follow-up examina-
tions, 836 individuals were lost to fol-
low-up or were nonclassiﬁable, resulting
in 2,593 high-risk individuals with rele-
vant data for the calculation of the pro-
gression rates in the high-risk group,
separately. These analyses include all in-
dividuals with relevant follow-up data for
the direct progression rates from baseline
to 5 years and high-risk individuals with
relevant follow-up data from 1, 3, or 5
years (n  4,615).
To calculate the crude progression
rates in this study, the Inter99 study was
analyzed as if it were a cohort study. Par-
ticipants in the low-risk group were only
examined at baseline and at the 5-year
follow-up.Hence,whenwecalculatedthe
overall progression rates in the Inter99
study for both the high-risk and the low-
risk groups combined, only information
from baseline and the 5-year follow-up
was used. Incident cases were deﬁned as
individuals with newly detected i-IFG,
i-IGT, IFG-IGT, or diabetes/self-reported
diabetes at the 5-year examination.
Progression rates for the high-risk
group were calculated separately, and all
information on glucose tolerance status
from the 1-, 3-, and 5-year follow-up ex-
aminations was used. Incident cases were
deﬁned as individuals with newly de-
tected i-IFG, i-IGT, IFG-IGT, or diabetes/
self-reported diabetes at the 1-, 3-, or
5-year examinations. Diabetes is consid-
eredanabsorbingstate.Thus,individuals
with known diabetes were not offered an
OGTT at subsequent examinations. Indi-
viduals without diabetes may change glu-
cose tolerance status between the
examinations. Hence, an individual may
progress to different states of glucose in-
tolerance at different time points and
thereby be included in more than one of
the subanalyses. In this study we did not
lookatregressioninglucosetolerancesta-
tus during follow-up.
Statistical analysis
Statistical analyses were performed using
SAS (version 9.1; SAS Institute, Cary,
NC). Exact 95% CIs were calculated for
proportions. Proportions were compared
between groups using 
2 tests. The Wil-
coxon signed-rank test was used to com-
pare means of continuous variables.
Progression rates were estimated by
dividing the number of outcomes by per-
son-years at risk using interval-censoring
(19). Years at risk were calculated as the
time difference between date of entry and
date of exit. Date of entry was the date of
the baseline examination. For individuals
progressing to a relevant outcome, the
date of exit was set at the midpoint be-
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ﬁrstexamination,wheretheoutcomewas
identiﬁed.Thiswastoaccountforthefact
that progressors will have converted at an
unknown time somewhere between their
date of entry and exit. For nonprogres-
sors, the date of exit was set at the date of
their last recorded OGTT. Rate ratios
were estimated as the ratio between two
progression rates.
RESULTS— Table1showstheclinical
characteristics of the study participants
according to glucose tolerance status at
baseline.Atotalof13.3%hadanabsolute
risk of IHD in the upper quintile of their
age and sex strata, and 56.2% were de-
ﬁned as being at high risk.
Of 6,006 individuals without diabe-
tes at baseline, 4,615 (76.8%) were fol-
lowedup.Moremen(50.7vs.44.4%,P
0.0001), older individuals (46.4 vs. 43.9
years,P0.0001),moreindividualswith
Danish nationality (95.9 vs. 3.2%, P 
0.0001), less individuals at high risk
(56.2 vs. 60.1%, P  0.01), and less indi-
vidualswithanabsoluteriskofIHDinthe
upper quintile of their age and sex strata
(13.3 vs. 1.1%, P  0.0001) were exam-
ined at follow-up compared with individ-
uals lost to follow-up. Individuals with
follow-up information had higher waist
circumference (86.1 vs. 85.4 cm, P 
0.048) than individuals lost to follow-up.
The progression rates from NGT
and/or impaired glucose regulation to
moreadvancedstagesofimpairedglucose
regulation and/or diabetes are presented
forallstudyparticipants(Table2)andfor
the high-risk group, separately (Table 3).
AsshowninTable2,individualswith
NGT progressed to impaired glucose reg-
ulation at a rate of 1.9% per year, and
0.3% per year progressed to diabetes. Of
all individuals with impaired glucose reg-
ulation, 4.0% per year progressed to dia-
betes. The progression rates from i-IFG,
i-IGT, and IFG-IGT to diabetes were 8.3,
12.7, and 31.0 times higher, respectively,
than the progression rate from NGT to
diabetes.
In the high-risk group (Table 3), in-
dividuals with NGT progressed to im-
pairedglucoseregulationatarateof5.5%
per year, and 0.4% per year progressed to
diabetes. The progression rate from i-IFG
toIFG-IGT(4.0%peryear)wasone-third
higher than the rate from i-IGT to IFG-
IGT (2.7% per year), whereas the rate
from i-IFG to diabetes was similar to the
rate from i-IGT to diabetes (3.7% per
year).Morethan10%peryearprogressed
from IFG-IGT to diabetes.
Table 1—Clinical characteristics of the participants with relevant follow-up data according to glucose tolerance status at baseline
NGT i-IFG i-IGT IFG-IGT Total
n (% of total) 3,599  78.0 414  9.0 433  9.4 169  3.7 4,615
Men (%) 48.0 (46.4–49.7) 74.4 (69.9–78.5)* 42.7 (38.0–47.5)† 69.8 (62.3–76.6)* 50.7 (49.3–52.2)
Danish nationality (%) 96.1 (95.5–96.8) 97.8 (95.9–99.0) 91.8 (88.7–94.2)‡ 97.0 (93.2–99.0) 95.9 (95.3–96.5)
Age (years) 45.7  7.7 49.3  6.9* 48.1  7.8* 50.0  6.8* 46.4  7.7
BMI (kg/m²) 25.5  4.0 27.7  4.5* 27.7  5.2* 29.2  4.9* 26.0  4.3
Waist circumference (cm) 84.3  12.1 93.6  11.7* 89.4  14.2* 96.2  11.9* 86.1  12.7
High-risk group (%) 48.1 (46.5–49.7) 62.8 (57.9–67.5)* 100 (99.2–100)* 100 (97.8–100)* 56.2 (54.7–57.6)
Absolute risk of IHD in upper quintile
of age and sex strata (%) 12.3 (11.3–13.5) 15.2 (11.9–19.0) 17.3 (13.9–21.2)† 19.5 (13.8–26.3)† 13.3 (12.4–14.3)
Data are proportions (95% CI) or means  SD, unless otherwise indicated. *P  0.0001 compared with NGT. †P  0.05 compared with NGT. ‡P  0.0001
compared with NGT.
Table 2—Progression rates to impaired glucose regulation and diabetes directly from baseline to 5-year follow-up in the combined low- and
high-risk group
Glucose tolerance
status at baseline n*
Glucose tolerance status at
5-year follow-up
Outcomes
(n) Person-years
Rate per 100
person-years
(95% CI)
NGT 3,187 i-IFG 83 16,918 0.5 (0.4–0.6)
i-IGT 192 16,621 1.2 (1.0–1.3)
IFG-IGT 28 17,063 0.2 (0.1–0.2)
i-IFG, i-IGT, or IFG-IGT 303 16,328 1.9 (1.7–2.1)
Diabetes 44 17,019 0.3 (0.2–0.3)
i-IFG, i-IGT, IFG-IGT, or diabetes 347 16,210 2.1 (1.9–2.4)
i-IFG 359 IFG-IGT 23 1,864 1.2 (0.8–1.9)
Diabetes 45 1,804 2.5 (1.9–3.3)
IFG-IGT or diabetes 68 1,743 3.9 (3.1–4.9)
i-IGT 354 IFG-IGT 13 1,866 0.7 (0.4–1.2)
Diabetes 66 1,722 3.8 (3.0–4.9)
IFG-IGT or diabetes 79 1,688 4.7 (3.8–5.8)
IFG-IGT 131 Diabetes 52 560 9.3 (7.1–12.2)
i-IFG, i-IGT, or IFG-IGT 844 Diabetes 163 4,087 4.0 (3.4–4.7)
NGT, i-IFG, i-IGT, or IFG-IGT 4,031 Diabetes 207 21,106 1.0 (0.9–1.1)
*Number of individuals at baseline.
Progression rates in the Inter99 study
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ulation-based study with a 5-year follow-
up, we found that 2% per year of all
individuals with NGT at baseline pro-
gressed to impaired glucose regulation or
diabetes. Among individuals at high risk
with NGT at baseline, almost 6% per year
progressed to impaired glucose regula-
tionordiabetes.Thisrelativelyhigherrate
of progression in the high-risk group
compared with the combined group was
expected, because at least one criterion
for being in the high-risk group was obe-
sity, which is a well-known risk factor for
diabetes(1,7).Furthermore,thehigh-risk
individuals were additionally reexamined
at 1 and 3 years, which makes any pro-
gression in glucose tolerance status more
likelytobedetectedandatanearliertime,
thus decreasing their risk time and in-
creasing the progression rate. On the
otherhand,thehigh-riskgroupwasoffered
a relatively more intensive intervention that
could underestimate the spontaneous pro-
gression rates in this group.
Among individuals with impaired
glucose regulation, 4% per year in the
combined low- and high-risk group and
almost5%peryearinthehigh-riskgroup
progressed to diabetes. All individuals
with i-IGT or IFG-IGT were in the high-
risk group in this study because IGT was
one of the criteria for being considered at
highrisk.Therefore,theprogressionrates
from i-IGT to IFG-IGT and/or diabetes
and from IFG-IGT to diabetes are almost
the same among all of the study partici-
pants(Table2)andinthehigh-riskgroup
(Table 3). However, the use of up to four
OGTT examinations in calculating the
progression rates in Table 3 makes these
ratesmoreaccuratethantheratesinTable
2, which only use baseline and 5-year
measurements.
In the high-risk group, the progres-
sion rate from IFG-IGT to diabetes was
2.8 times higher than the progression
rates from the isolated states of impaired
glucoseregulation,i-IFGandi-IGT,todi-
abetes. This was expected because the
IFG-IGT group has more severe meta-
bolic abnormalities than the isolated
states (15) and therefore has an increased
risk of progression to diabetes. In addi-
tion, the risk of misclassiﬁcation is lower.
Both FPG and 2-h plasma glucose can be
randomlyhigh,butbecausetheclassiﬁca-
tion of IFG-IGT requires both an abnor-
mal FPG and an abnormal 2-h plasma
glucose, there is a low risk of a simulta-
neously random high FPG and 2-h
plasma glucose.
In the present follow-up study, we
analyzed the Inter99 study as if it was a
cohort study, but because the Inter99
study was designed as an intervention
study,theratesofprogressionmighthave
been higher without the intervention.
However, for the high-risk group, the
group-based intervention (high-intensity
group A) had no additional effect beyond
the individualized intervention (low-
intensity group B) with respect to plasma
glucose levels (C.L., D.V., Ulla Toft, Inge
Tetens, O.P., T.J., K.B.-J., unpublished
observations). A recent study from the
Danish National Diabetes Register has
shown age- and sex-speciﬁc incidence
rates in the Danish population (20) that
are approximately one-third of the rate
of progression to diabetes in our study
(1.0% per year, Table 2). This reﬂects an
underdiagnosing of diabetes in the back-
ground population, and, therefore, we
cannot estimate the total effect of the life-
style intervention in the Inter99 popula-
tionbycomparingourﬁndingswiththose
forthebackgroundpopulationviacentral
registries in Denmark.
Although the Inter99 study is poten-
tially underestimating the spontaneous
progression rates because of the lifestyle
intervention, we compared the rate ratios
with those from the few European popu-
lation-based studies that have calculated
progression rates from NGT or impaired
glucose regulation to diabetes in Cauca-
sians using the current WHO classiﬁca-
tion criteria (10,11,13). These studies
have not calculated progression to
impaired glucose regulation. None of
the studies have performed interval-
censoring in the calculation of progres-
sionrates,and,thus,theyhavepotentially
underestimated their crude rates. We
have chosen not to compare the high-risk
group with highly selected European
populations (21,22) because of different
criteria for being at high risk.
In the Dutch Hoorn study, 1,342
white Caucasians aged 50–75 years with-
Table3—Progressionratestoimpairedglucoseregulationanddiabetesfrombaselinethrough1-and3-yearto5-yearfollow-upforindividuals
in the high-risk group
Glucose tolerance
status at baseline n*
Glucose tolerance status at 1-,
3-, or 5-year follow-up
Outcomes
(n) Person-years
Rate per 100
person-years
(95% CI)
NGT 1,731 i-IFG 167 7,602 2.2 (1.9–2.6)
i-IGT 208 7,543 2.8 (2.4–3.2)
IFG-IGT 50 7,995 0.6 (0.5–0.8)
i-IFG, i-IGT, or IFG-IGT 384 6,939 5.5 (5.0–6.1)
Diabetes 33 8,058 0.4 (0.3–0.6)
i-IFG, i-IGT, IFG-IGT, or diabetes 401 6,887 5.8 (5.3–6.4)
i-IFG 260 IFG-IGT 44 1,112 4.0 (2.9–5.3)
Diabetes 42 1,121 3.7 (2.8–5.1)
IFG-IGT or diabetes 81 1,005 8.1 (6.5–10.0)
i-IGT 433 IFG-IGT 52 1,928 2.7 (2.1–3.5)
Diabetes 70 1,882 3.7 (2.9–4.7)
IFG-IGT or diabetes 111 1,737 6.4 (5.3–7.7)
IFG-IGT 169 Diabetes 63 604 10.4 (8.2–13.4)
i-IFG, i-IGT, or IFG-IGT 862 Diabetes 175 3,607 4.9 (4.2–5.6)
NGT, i-IFG, i-IGT, or IFG-IGT 2,593 Diabetes 208 11,6642 1.8 (1.6–2.0)
*Number of individuals at baseline.
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were followed for 6.4 years. The progres-
sionratesfromi-IFG,i-IGT,andIFG-IGT
to diabetes were 7.3, 8.3, and 16.0 times
higher, respectively, than the progression
rate from NGT to diabetes (0.7 per 100
person-years) (10). These rate ratios are
alllowerthanthesimilarrateratiosinour
study.
In the Asturias study from Northern
Spain, 630 mostly Caucasians aged
30–75 years without diabetes at baseline
in 1998–1999 were followed for 6.3
years. The progression rates from i-IFG,
i-IGT, and IFG-IGT to diabetes were 6.9,
4.2, and 19.0 times higher, respectively,
than the progression rate from NGT to
diabetes (0.5 per 100 person-years) (11).
The rate ratios are all lower than the rate
ratios in our study.
The British Ely study included 1,040
nondiabetic individuals aged 40–69
years of predominately white-European
origin. An OGTT was performed at base-
line in 1990–1992 and at the 4.5- and
10-year follow-up examinations (13).
The Ely study used a lower threshold
(5.6 mmol/l) for deﬁning NGT than
that recommended by the WHO in 1999
(6.1 mmol/l) (9), and, therefore, the
rates would have been higher if the WHO
deﬁnition of NGT had been used. The ra-
tio between the rate of progression from
IFG to diabetes and the rate of progres-
sion from NGT to diabetes (0.2 per 100
person-years) was 7.3, which is lower
than the rate ratios comparing progres-
sion to diabetes from i-IFG or IFG-IGT
and NGT in our study.
Strengths of the present population-
based study include its large size with
4,615 participants at baseline with fol-
low-up data. Furthermore, the study was
initiated 10 years ago, which is impor-
tant because the rates of progression in a
given population change over time
(23,24) because of changes in modiﬁable
riskfactors(e.g.,BMIandlevelofphysical
activity) and in the demography of the
population.Furtherstrengthsarethesep-
aration of impaired glucose regulation
into i-IFG, i-IGT, and IFG-IGT and
thereby the presentation of progression
ratestoandfromtheisolatedstatesaswell
as the combined state. The multiple ex-
aminations with OGTTs in the high-risk
group make the progression rates among
high-riskindividualsveryaccurate.Other
strengths are the calculation of person-
years at risk and the use of interval-
censoring, which takes into account the
fact that conversion to a more severe glu-
cosetolerancestateoccursbeforethetime
of the examination.
As mentioned above, the spontane-
ous progression rates may be underesti-
mated because the Inter99 study is an
intervention study. A further limitation of
this study is the loss to follow-up. How-
ever, a follow-up rate of 76.8% is compa-
rable to that for the Hoorn study (73.5%)
(10),theAsturiasstudy(75.5%)(11),and
the Ely study (72%) (13). In accordance
with the WHO 1999 criteria, the classiﬁ-
cation of glucose tolerance status in this
epidemiologicalstudywasbasedonasin-
gle OGTT examination (9). Nevertheless,
because of the known high intraindi-
vidual variation in plasma glucose levels,
especiallyforpostloadglucose,somemis-
classiﬁcation might have occurred when
participantswerecategorizedintoglucose
tolerance categories (10). Furthermore,
there is an additional risk of misclassiﬁca-
tionbecausewedidnotlookatregression
in glucose tolerance status during follow-
up.However,becausetherewasnodiffer-
ence in plasma glucose between the
intervention groups, we consider the risk
of misclassiﬁcation to be random.
Therelativelylowparticipationrateat
baseline (52.5%) introduces a selection
bias and weakens the possibility of gener-
alizing the results. Nevertheless, it does
not affect the validity of the progression
rates in this study.
Therateratiosinourstudyarehigher
than similar rate ratios in the few other
European studies, which also used the
current WHO classiﬁcation. This may be
due to a relatively low progression rate
fromNGTtodiabetesintheInter99study
compared with that in the Hoorn and the
Asturias study. The NGT group has a
lower proportion of high-risk individuals
than the other glucose tolerance groups
(Table 1). Therefore, the relatively low
progression rate from NGT to diabetes
compared with the rates from impaired
glucose regulation to diabetes cannot be
attributed to an intervention effect. Al-
though the rate ratios in our study are
higher than those in the other European
studies, the pattern is the same with rela-
tively low rates of progression from NGT
to diabetes, intermediate rates from i-IFG
andi-IGTtodiabetes,andhighratesfrom
IFG-IGT to diabetes.
In summary, we have presented for
the ﬁrst time progression rates to i-IFG,
i-IGT, and IFG-IGT in a large European
population-based study, which uses the
current WHO classiﬁcation criteria. Pro-
gression rates to diabetes show the same
pattern as that seen in the few similar Eu-
ropean studies.
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